Cologuard Plus wins European clearance: what it means for Exact Sciences stock

Published on 10/21/2026 at 04:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CE Mark opens a European route for Cologuard Plus after a USD 21.00 billion deal. Exact Sciences stock is now part of Abbott's diagnostics portfolio.

European launch follows ownership change

Cologuard Plus received CE Mark on October 20, 2026.
Abbott completed the USD 21.00 billion Exact Sciences deal on March 23, 2026.
The pivotal study reported 95.00 percent sensitivity and 94.00 percent specificity among 20,000 participants.

Isometrisches 3D-Diagramm der Diagnostik-Wertschöpfungskette von Exact Sciences Corp. US30063P1057 — Exact Sciences Corp. visualisiert die gesamte Krebsdiagnostik Wertschöpfungskette als isometrisches 3D Diagramm US30063P1057, Illustration mit AI erstellt.

Exact Sciences (ISIN US30063P1057) reached a new commercial milestone on October 20, 2026, when its Cologuard Plus colorectal cancer screening test received a CE Mark for Europe. The development matters for Exact Sciences stock because the test is now being prepared for a phased European rollout inside Abbott's cancer diagnostics business, as MassDevice reported.

European clearance creates a route to rollout

MassDevice reported that the test will be introduced in selected European markets, with timing depending on reimbursement and local readiness. The same report said the pivotal study included 20,000 participants and showed 95.00 percent sensitivity for colorectal cancer and 94.00 percent specificity.

The product is designed for at-home stool collection and does not require bowel preparation, dietary restrictions or sedation. A positive result still directs the patient toward a confirmatory colonoscopy, making adoption, reimbursement and follow-up care central to the commercial opportunity.

Three dates define the transition

On November 19, 2025, Abbott agreed to acquire Exact Sciences for USD 21.00 billion, with shareholders set to receive USD 105.00 per share, according to Simply Wall St. On March 23, 2026, Abbott completed the acquisition and Exact Sciences became a subsidiary. On October 20, 2026, Cologuard Plus received its European CE Mark.

What does the ownership change mean?

The ownership change shifts the investment lens from a standalone Exact Sciences listing to Abbott's execution of the acquired diagnostics portfolio. Exact Sciences' website describes its business as cancer prevention, screening and therapy guidance, including Cologuard Plus and the Oncotype DX testing family, Exact Sciences.

Upcoming reporting date

Abbott was scheduled to release third-quarter 2026 financial results on October 21, 2026, before the market opened, IB Madison reported. Those results provide the next dated checkpoint for how the acquired cancer diagnostics business is being incorporated into Abbott's wider portfolio.

Exact Sciences now operates inside Abbott

For investors, the October 20 CE Mark links Exact Sciences' former screening platform to a new geographic expansion path, while commercial execution and reimbursement will determine how quickly that opportunity develops.